Quick Dispatch:
Your roche glp-1 Roche Invests $5.3B in Zealand's Petrelintide, an Obesity Drug Candidate orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your roche glp-1 Roche Invests $5.3B in Zealand's Petrelintide, an Obesity Drug Candidate ships.
Need Help?
Questions about roche glp-1 Roche Invests $5.3B in Zealand's Petrelintide, an Obesity Drug Candidate, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for roche glp-1 Roche Invests $5.3B in Zealand's Petrelintide, an Obesity Drug Candidate in your area.
![Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity](https://a.storyblok.com/f/176343/1920x1281/88773444bc/roche_279855.png)
Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity
23.14
The next wave of GLP-1 medications could make weight management easier — and more personalized — than ever. Drugmakers like Pfizer, Amgen, Eli Lilly, Roche, Structure Therapeutics, and Novo Nordisk are working
21.04
Roche's Genentech vows to expand NC anti-obesity drug plant
22.21
Roche Announces Positive Topline Results from Phase II Study for Dual GLP-1/GIP Receptor Agonist
28.12
Roche broadens obesity drug plans with $1.65B Zealand deal
29.83
Roche announces positive phase II results for dual GLP-1/GIP receptor
24.32
Roche aiming for 'top 3' position in obesity space as lead asset progresses
28.19
.png?width=901&height=1201&name=Tirzepatide%20Image%20900x1200%20(vial%20only).png)
